|
Patient/Gender
|
RETmutation
|
Age
|
Pre-Ct (ng/L)
|
CEA (ng/ml)
|
Tumor size* (cm): L/R
|
Operative procedure
|
Histology
|
pTNM
|
LNM
|
Post-Ct (ng/L)
|
Interval time (years)
|
|---|
|
F3-III8/F
|
C634Y
|
41
|
1744.0
|
57.9
|
1.4/3.2
|
Reject operation
|
-
|
-
|
-
|
-
|
18
|
|
F3-III9/F
|
C634Y
|
37
|
206.0
|
12.2
|
1.0/0.7
|
Reject operation
|
-
|
-
|
-
|
-
|
18
|
|
F3-IV1/M
|
C634Y
|
22
|
11.8
|
1.8
|
-/0.3
|
Reject operation
|
-
|
-
|
-
|
-
|
18
|
|
F3-IV4/F
|
C634Y
|
9
|
9.8
|
0.7
|
0.3/0.2
|
Reject operation
|
-
|
-
|
-
|
-
|
18
|
|
F4-III2/F
|
C634Y
|
18
|
118.0
|
6.8
|
1.0/1.0
|
TT + B-VI
|
MTC
|
T1N0M0
|
0/5
|
<2.0
|
17
|
|
F5-III4/F
|
C634R
|
19
|
24.3
|
2.9
|
0.3/0.2
|
TT
|
MTC
|
T1N0M0
|
NO
|
<2.0
|
17
|
|
F6-III2/M
|
C634R
|
21
|
20.9
|
2.7
|
0.5/0.7
|
TT + B-VI
|
MTC
|
T1N0M0
|
0/3
|
<2.0
|
26
|
|
F6-III4/M
|
C634R
|
21
|
1769.0
|
119.6
|
1.1/1.0
|
TT + B-VI + R-LND
|
MTC
|
T1N1bM0
|
20/59
|
975.0
|
23
|
|
F6-III5/F
|
C634R
|
19
|
71.4
|
3.3
|
0.5/1.0
|
TT + B-VI
|
MTC
|
T1N0M0
|
0/1
|
<2.0
|
26
|
|
F7-III2/F
|
C618R
|
26
|
487.6
|
25.9
|
2.0/2.5
|
Reject operation
|
-
|
-
| |
-
|
17
|
|
F8-II2/F
|
C618Y
|
78
|
1758.0
|
106.0
|
3.0/3.5
|
Reject operation
|
-
|
-
| |
-
|
19
|
|
F8-III5/M
|
C618Y
|
53
|
<2.0
|
2.2
|
−/−
|
Awaiting surgery
|
-
|
-
| |
-
|
19
|
|
F8-IV5/F
|
C618Y
|
26
|
5.8
|
2.0
|
−/−
|
TT
|
CCH
|
-
|
NO
|
<2.0
|
19
|
- Note: Ct (basal serum Ct): normal <8.4 ng/L for male and <5.0 for female by FACLIA ; CEA (carcinoembryonic antigen): normal ≤ 5.0 ng/ml; Pre-Ct, pre-surgical Ct; Post-Ct, post-surgical Ct; TT, total thyroidectomy; B-VI, bilateral level VI lymph node dissection; R/ L -LND, right/ left lymph neck dissection.
- *Tumor size was measured by ultrasonography.
